Proto Labs Inc (PRLB)
Official siteINDUSTRIALS • METAL FABRICATION • NYSE
Market Cap: $1.61B
Last updated: Nov 17, 2026 at 11:06 AM ET
Proto Labs Inc (PRLB) Stock Forecast
Analysts expect Proto Labs (PRLB) to earn $2.27 per share in the fiscal year ending Dec 31, 2026, on revenue of $590.60M. Of 5 analysts, 4 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 5 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 5 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 80% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 20.0% |
| Buy | 3 | 60.0% |
| Hold | 1 | 20.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 5
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 10.6% and revenue estimates rise 7.0%.
- Fiscal year ending Dec 31, 2026
- $2.27
- EPS consensus, revenue $590.60M
- Fiscal year ending Dec 31, 2027
- $2.51
- EPS consensus, revenue $632.10M
- Next report
- Feb 4, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $2.27 | $2.26 to $2.27 | 5 | $590.60M | $590.00M to $591.20M | 5 |
| Dec 31, 2027 | $2.51 | $2.45 to $2.59 | 4 | $632.10M | $630.12M to $635.00M | 4 |
Quarterly Estimates
The EPS consensus rises from $0.51 for the quarter ending Dec 31, 2026 to $0.56 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.51 | $0.48 to $0.54 | 7 | $150.54M | $144.06M to $155.61M | 7 |
| Mar 31, 2027 | $0.56 | $0.53 to $0.58 | 4 | $151.57M | $150.80M to $152.90M | 4 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 10 upward and 1 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 5 | 0 |
| Fiscal year ending Dec 31, 2027 | 3 | 0 |
| Quarter ending Mar 31, 2027 | 2 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 2.7% from $2.21.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $2.27 | $2.21 | $2.21 | $2.21 | $2.21 | +2.3% |
| Fiscal year ending Dec 31, 2027 | $2.51 | $2.40 | $2.39 | $2.39 | $2.39 | +5.2% |
| Quarter ending Mar 31, 2027 | $0.56 | $0.55 | $0.55 | $0.55 | $0.55 | +1.5% |
Frequently Asked Questions About PRLB
What is the PRLB stock forecast?
Consensus analyst estimates put Proto Labs's EPS at $2.27 for the fiscal year ending Dec 31, 2026, on revenue of $590.60M. The consensus rating from 5 analysts is Buy.
How do analysts rate PRLB stock?
Of 5 analysts covering Proto Labs, 1 rates it Strong Buy, 3 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from PRLB next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $2.27, with estimates from $2.26 to $2.27 from 5 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $2.51, with estimates from $2.45 to $2.59 from 4 analysts.
What revenue do analysts expect from Proto Labs next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $590.60M, with estimates from $590.00M to $591.20M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $632.10M, with estimates from $630.12M to $635.00M.
How many analysts cover PRLB?
5 analysts rate Proto Labs stock, and 5 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
PRLB pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts